Cargando…
Solriamfetol Titration and AdministRaTion (START) in Patients with Obstructive Sleep Apnea: A Retrospective Chart Review and Hypothetical Patient Scenario
INTRODUCTION: Solriamfetol (Sunosi™), a dopamine/norepinephrine reuptake inhibitor, is approved (USA and EU) to treat excessive daytime sleepiness (EDS) in adults with obstructive sleep apnea (OSA) (37.5–150 mg/day). Real-world research on solriamfetol initiation is limited. The objective of this st...
Autores principales: | Singh, Haramandeep, Hyman, Danielle, Parks, Gregory S., Chen, Abby, Foley, Catherine, Baldys, Beth, Ito, Diane, Thorpy, Michael J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402730/ https://www.ncbi.nlm.nih.gov/pubmed/35927541 http://dx.doi.org/10.1007/s12325-022-02249-4 |
Ejemplares similares
-
P148 Solriamfetol Titration & AdministRaTion (START): Dosing and titration strategies in patients with narcolepsy starting solriamfetol
por: Thorpy, M, et al.
Publicado: (2021) -
P147 Solriamfetol Titration & AdministRaTion (START): Characteristics of patients with obstructive sleep apnoea (OSA) and prescriber rationale for starting treatment with solriamfetol
por: Singh, H, et al.
Publicado: (2021) -
A randomized study of solriamfetol for excessive sleepiness in narcolepsy
por: Thorpy, Michael J., et al.
Publicado: (2019) -
Solriamfetol for the Use of Narcolepsy: A Systematic Review
por: Iturburu, Alisson, et al.
Publicado: (2022) -
Profile of Solriamfetol in the Management of Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea: Focus on Patient Selection and Perspectives
por: Abad, Vivien C
Publicado: (2021)